🇺🇸 FDA
Patent

US 10857231

Formulations of VEG antagonist fusion proteins and method of manufacturing them

granted A61KA61K31/4172A61K31/7012

Quick answer

US patent 10857231 (Formulations of VEG antagonist fusion proteins and method of manufacturing them) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Dec 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
114
CPC classes
A61K, A61K31/4172, A61K31/7012, A61K38/16, A61K38/179